C12N 2740/16052
Relating to complementing cells and packaging systems for producing virus or viral
Official title: relating to complementing cells and packaging systems for producing virus or viral particles
C12N2740/16052 (Relating to complementing cells and packaging systems for producing virus or viral) appears on 144 US grants and 225 published applications in this corpus.
Search patents in C12N- Granted patents
- 144
- Published applications
- 225
- Assignees
- 124
- Inventors
- 409
- Latest grant
- 31 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 3 | 0 |
| 1999 | 5 | 0 |
| 2000 | 4 | 0 |
| 2001 | 8 | 1 |
| 2002 | 3 | 6 |
| 2003 | 7 | 16 |
| 2004 | 10 | 5 |
| 2005 | 5 | 8 |
| 2006 | 3 | 5 |
| 2007 | 9 | 5 |
| 2008 | 2 | 9 |
| 2009 | 2 | 4 |
| 2010 | 5 | 5 |
| 2011 | 3 | 6 |
| 2012 | 6 | 4 |
| 2013 | 2 | 2 |
| 2014 | 3 | 6 |
| 2015 | 3 | 7 |
| 2016 | 4 | 3 |
| 2017 | 5 | 5 |
| 2018 | 2 | 10 |
| 2019 | 4 | 13 |
| 2020 | 1 | 15 |
| 2021 | 10 | 17 |
| 2022 | 5 | 12 |
| 2023 | 9 | 13 |
| 2024 | 6 | 26 |
| 2025 | 14 | 19 |
| 2026 | 1 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof31 Mar 2026US 12,590,321 B2Exuma Biotech Corp.
- Vector system for expressing regulatory RNA9 Sep 2025US 12,410,445 B2American Gene Technologies International Inc.
- Lentiviral-based vectors and related systems and methods for eukaryotic gene editing26 Aug 2025US 12,398,182 B2Wake Forest University Health Sciences
- Methods and constructs for transient production of lentiviral vector26 Aug 2025US 12,398,404 B2Lonza Walkersville, Inc.
- Methods and constructs for production of lentiviral vector19 Aug 2025US 12,391,960 B2Lonza Walkersville, Inc.
- Methods and kits for the improved fermentative production of a recombinant virus20 Aug 2026US 2026/0242822 A1Takeda Pharmaceutical Company Limited
- Pseudotyped viral particles for targeting tcr-expressing cells6 Aug 2026US 2026/0226500 A1Regeneron Pharmaceuticals, Inc.
- Use of lentiviral vectors expressing factor ix23 Jul 2026US 2026/0209799 A1Bioverativ Therapeutics Inc.
- Retroviral and Lentiviral Vectors25 Dec 2025US 2025/0388929 A1Autolus Limited
- Manufacturing viral particles18 Dec 2025US 2025/0382586 A1Umoja Biopharma, Inc.
Most cited
By later US patents
- Method and means for producing high titer, safe, recombinant lentivirus vectors261US 5,994,136 ACell Genesys, Inc. · 1999
- Lentivirus vector system92US 6,790,657 B1The United States of America as represented by the Department of Health and Human Services · 2004
- Method and means for producing high titer, safe, recombinant lentivirus vectors89US 6,165,782 ACell Genesys, Inc. · 2000
- Expression of HIV polypeptides and production of virus-like particles73US 6,602,705 B1Chiron Corporation · 2003
- Lentiviral vectors72US 6,207,455 B12001